At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 424 enrolled
Drug / intervention
adalimumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis
In Brief
A Phase 3 clinical trial evaluating adalimumab for Uveitis. Completed, enrolled 424 participants.
Detailed Summary
The purpose of this study is to evaluate the long term efficacy and safety of adalimumab participants with non-infectious intermediate-, posterior- or pan-uveitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUveitis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2010
Enrollment StartNov 2010
Primary CompletionMay 2018
TodayJul 2026
First PostedJun 22, 2010
Enrollment StartNov 23, 2010
Primary CompletionMay 21, 2018
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 16.0 years ago
Interventions
adalimumabdrug
Adalimumab, pre-filled syringe, administered by SC injection